Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment

JAMA Ophthalmology

Volumn 131, Issue 2, 2013, Pages 139-145

  Do, Diana V ^a   Nguyen, Quan D ^a   Khwaja, Afsheen A ^a   Channa, Roomasa ^a   Sepah, Yasir J ^a   Sophie, Raafay ^a   Hafiz, Gulnar ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN; HEMOGLOBIN A1C; RANIBIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINAL THICKNESS; RETREATMENT; VISUAL ACUITY;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84874080959     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamaophthalmol.91     Document Type: Article

References (7)

1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4): 520-526.
2. Klein R, Klein B. Vision disorders in diabetes. In: National Diabetes Data Group of the National Institute of Diabetes and Digestive and Kidney Diseases, ed. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995:293-330.
3. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142(6): 961-969.
4. Nguyen QD, Shah SM, Heier JS, et al; READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. Ophthalmology. 2009;116(11):2175-2181, e1. doi:10.1016/j.ophtha.2009.04.023.
5. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study [published correction appears in Ophthalmology. 2011;118(6):1016]. Ophthalmology. 2010;117(11):2146-2151.
6. Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077.e35. doi:10.1016/j.ophtha.2010.02.031.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: Ranibizumab Monotherapy or Combined With Laser Versus Laser Monotherapy for Diabetic Macular Edema. Ophthalmology. 2011;118(4):615-625.